Efficacy of Traditional Chinese Medicine in the Treatment of Rash Caused by Epidermal Growth Factor Receptor Inhibitors: A Frequency Statistics and Meta‑Analysis

Objective: The aim of this study is to evaluate the efficacy of Traditional Chinese Medicine (TCM) in the treatment of rash caused by epidermal growth factor receptor inhibitors (EGFRIs). Materials and Methods: Foreign language database (such as PubMed, Web of Science, Cochrane Library, EMBASE) and Chinese language database (such as China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals [VIP], Wangfang, CBM disc) were searched for all trials of TCM in the treatment of rash caused by EGFRIs until January of 2019. We also looked through the references of relevant studies to supplement additional trials. The SPSS 25.0 was used for statistics of TCM with high frequency, and Review Manager 5.3 was used for meta-analysis. Results: A total of 22 studies were included in the study. We selected TCM whose frequency were >3.0%. They were Lonicera japonica（金银花）, Licorice Roots Northwest Origin（生甘草）, Cortex Dictamni（白鲜皮）, Radix Sophorae Flavescentis（苦参）, Schizonepeta（荆芥）, Saposhnikovia Divaricate（防风）. The meta?analysis revealed that the efficacy of TCM in treating EGFRIs?related rash was better than that of Western medicine or none. Conclusions: TCM could significantly relieve rash caused by EGFRIs, which is worth popularizing. Moreover, the mechanism deserves to be further explored.     

Traditional Chinese medicine for acute mountain sickness prevention:A systematic review and meta-analysis of randomized controlled trialsOA

Objective: To evaluate the efficacy of traditional Chinese medicine(TCM) for preventing acute mountain sickness(AMS).Methods: We included randomized controlled trials(RCTs) which evalueded the effect of TCM for preventing AMS, compared with a placebo, no treatment or acetazolamide. The literature was searched in 6major databases. RevMan 5.4 software was used for the meta-analysis. The relative risk for discrete variables and the mean difference for continuous variables with 95% confidence interv...     

Randomized Clinical Trials of Constitutional Acupuncture： A Systematic Review

The aim of this systematic review is to compile and critically evaluate the evidence from randomized clinical trials （RCTs） for the effectiveness of acupuncture using constitutional medicine compared to standard acupuncture. Ten databases were searched through to December 2008 without language restrictions. We also hand-searched nine Korean journals of oriental medicine. We included prospective RCTs of any form of acupuncture with or without electrical stimulation. The included trials had to investigate constitutional medicine. There were no restrictions on population characteristics. Forty-one relevant studies were identified, and three RCTs were included. The methodological quality of the trials was variable.     

Effectiveness of redcore lotion in patients with vulvovaginal candidiasis: a systematic review and Meta-analysis

OBJECTIVE:To summarize and evaluate the effectiveness and safety of Redcore lotion on treating vulvovaginal candidiasis(VVC) using a systematic review and Meta-analysis of randomized controlled trials. METHODS:A systematic literature search was performed in five English and three Chinese electronic databases up to October 2019. Randomized controlled trials in the treatment for VVC were included; only studies which compared the effectiveness and safety of Redcore lotion plus miconazole with micon...     

Current status of outcome reporting in randomized controlled trials of traditional Chinese medicine for mammary gland hyperplasia: A systematic reviewOA

Objective: To assess outcome indicators in clinical trials and provide a reference for establishing a core outcome set to treat hyperplasia of mammary gland(HMG) with traditional Chinese medicine(TCM).Methods: Eight online databases were searched from their inception to December 31, 2022, to assess outcomes reported in randomized controlled trials(RCTs) of HMG treated with TCM. The quality of the included studies was assessed according to the Cochrane Risk of Bias Assessment Tool. All outcomes w...     

Antiviral Properties of Traditional Chinese Medicine against Coronavirus: Research Clues for Coronavirus Disease-2019

The objective of this study was to provide research clues for the prevention and treatment of coronavirus disease?2019 (COVID?19) and coronavirus (CoV) infection using Traditional Chinese Medicine (TCM). A review on research and clinical trials that using TCM extracts and active ingredients against CoV was performed, and a table of TCM agents and their effects on CoV were summarized. Relevant analysis was performed and visual expression of the data included summarizing the types of TCM and treatment methods for COVID?19. TCM fighting against CoV is mainly used in the lung and heart channels, and its medicinal properties are mainly cold and mild, while its taste is mainly bitter and sweet. The majority of research focused on treatments that clear away heat and toxic materials and those that strengthen body resistance and tonify deficiencies. TCM has unique advantages to fight against CoV. The development of new anti?CoV therapy using TCM is of great significance for the prevention and treatment of COVID?19 pneumonia and various viral infectious diseases.     

Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease: a systematic review and Meta-analysis

OBJECTIVE: To evaluate the efficacy and safety of activating blood circulation and removing blood stasis in terms of Traditional Chinese Medicine(TCM) for managing renal fibrosis(RF) in patients with chronic kidney disease(CKD). METHODS: We searched randomized controlled trials(RCTs) from eight databases. RESULTS: Sixteen eligible studies with 1,356 participants were included in this study. Compared to treatment with Western Medicine(WM) alone, the combined treatment with activating blood circul...     

Rhubarb-based Chinese herbal formulae for hepatic encephalopathy: a systematic review and Meta-analysis

OBJECTIVE: To evaluate the effectiveness and safety of rhubarb-based Chinese herbal formulae(RCHF), which are widely used to treat hepatic encephalopathy(HE) in China.METHODS: Nine online databases were searched from inception to November 22, 2016. Eligible studies were randomized controlled trials of Traditional Chinese Medicine(TCM) treatment for adult patients(≥ 18 years old) with HE. Outcomes such as mortality rate, clinical response rate, blood ammonia level, and alanine aminotransferase were evaluated between TCM group and control group.RESULTS: Thirty studies involving 2661 HE patients were analyzed. Most studies used RCHF treatment.Compared with conventional treatment as usual,lactulose, and vinegar, RCHF were associated with significant improvement in clinical response rate[risk ratio(RR) = 1.33, 95% confidence interval(CI) =1.25, 1.43, I2= 0%; RR = 1.26, 95% CI = 1.14, 1.38, I2=22%; and RR = 1.19, 95% CI = 1.06, 1.33, I2= 0%, respectively] and significant reductions in levels of blood ammonia and alanine aminotransferase. Only minor RCHF-associated adverse events, such as abdominal pain(0.3%), anal tenesmus(0.3%), and diarrhea(2.3%), were reported, and there were no significant differences in these events between the treatment group and the three types of control group.CONCLUSION: The findings suggest that RCHF may be an alternative treatment option for HE patients. More rigorous multicenter studies with larger samples and longer observational periods are needed to confirm these findings.     

Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trialsOA

Objective: To evaluate the effectiveness and safety of seven oral Chinese patent medicines(CPMs) as adjuvant therapy for cancer-related anemia(CRA) by network meta-analysis(NMA).Methods: A literature search to obtain randomized controlled trials(RCTs) of seven oral CPMs in the adjuvant treatment of CRA was conducted in multiple databases from the inception to April 2022. The Rev Man5.3 and R 4.1.1 software were used for NMA.Results: We ultimately included 29 RCTs with 2140 patients. Traditional ...     

Clinical efficacy and safety of Traditional Chinese Medicine combined with Western Medicine in patients with diabetic acute ischemic stroke

OBJECTIVE： To observe the clinical efficacy and safety of Traditional Chinese Medicine （TCM） com- bined with Western Medicine （WM） in patients with diabetic acute ischemic stroke. METHODS： Ninety patients with diabetic acute ischemic stroke were randomly divided into a treat- ment group and a control group. The 45 patients in the treatment group were given standardized treat- ment with TCM combined with WM. They received corresponding oral Chinese decoctions three times daily, according to their TCM syndromes, along with basic western medical treatment. The 45 patients in the control group were given non-stan- dardized treatment with TCM combined with WM. They received an oral Chinese decoction for promo- tion of blood circulation to inhibit hemostasis, regardless of their TCM syndromes, along with ba- sic western medical treatment. The treatments lasted for 4 weeks. Scores were evaluated on the National Institutes of Health Stroke Scale （NIHSS） score, activity of daily life （ADL） scores, and TCM symptoms before treatment and 2 and 4 weeks after treatment. RESULTS： Analysis of variance for repeated mea- surements showed that there were significant dif- ferences in NIHSS and ADL score before and after treatment in both groups （P〈0.05）. There were also significant differences between the scores at 2 and 4 weeks after treatment. There were signifi- cant differences in TCM syndrome scores before and after treatment in both groups （P〈0.05）. There were also significant differences between the scores at 2 and 4 weeks after treatment. The X2 test showed no statistically significant difference in the incidence of adverse reactions between the two groups （P〉0.05）. CONCLUSION： Standardized treatment was supe- rior to non-standardized treatment for clinical efficacy of TCM combined with WM in patients with diabetic acute ischemic stroke, and the superiority was more obvious in improving neural dysfunction, ADL score, and TCM symptoms. The adverse reactions were similar in the two treatment groups.     

六味地黄丸联合西药治疗轻、中度阿尔茨海默病的临床观察

目的:观察六味地黄丸联合常规西药治疗轻、中度阿尔茨海默病(AD)的临床效果,初步探讨六味地黄丸治疗AD的机制。方法:选取2015年3月至2016年8月北京老年医院接受治疗的髓海不足、肾阴亏虚型轻、中度AD患者76例作为研究对象,随机分为对照组和联合组,每组38例。其中对照组患者给予盐酸多奈哌齐片治疗,联合组患者在此次基础上给予六味地黄丸。比较2组患者的治疗效果及治疗前后中医症状积分、简易智能状态检查表(MMSE)评分、AD评估量表认知部分(ADAS-cog)评分、日常生活能力量表评分(ADL)变化情况。结果:联合组治疗总有效率明显高于对照组(P0.05);治疗后2组患者的MMSE、ADAS-cog及ADL评分均明显得到改善,且治疗后联合组上述指标均明显优于对照组(P0.05);治疗后对照组患者中医症状积分无明显变化(P0.05),联合组则明显降低,且与对照组比较具有统计学意义(P0.05)。结论:六味地黄丸联合常规西药治疗轻中度AD效果显著,可明显改善患者的智力情况和生活能力,同时还可显著改善患者的中医症候,值得临床推广应用。     

六味地黄丸预防干扰素副反应的临床观察

目的：观察六味地黄丸对干扰素导致的骨髓抑制及不良反应的预防作用.方法：干扰素治疗的慢性肝炎患者160例,随机分六味地黄丸为治疗组80例,对照组80例.治疗组在应用干扰素治疗的同时口服六味地黄丸,对照组仅使用干扰素,丙肝患者两组同时加服利巴韦林.观察两组治疗后的白细胞（WBC）、中性粒细胞（N）、血小板（PLT）及治疗后的不良反应情况,疗程为4周.结果：与对照组相比,六味地黄丸可有效降低干扰素骨髓抑制及不良症状的发生率（P〈0.01）,差异有统计学意义.结论：六味地黄丸为预防干扰素副反应的有效方剂.     

六味地黄丸干预绝经后骨质疏松症患者基因表达谱分析

目的探讨中药六味地黄丸干预绝经后骨质疏松患者的分子机制并分析预测其靶标和药物作用通路。方法检索并下载GEO中与采用六味地黄丸干预绝经后骨质疏松症的微阵列基因表达数据集。通过获取的基因表达数据集,分析六味地黄丸干预前后绝经后骨质疏松症患者血液中差异表达基因变化,并将这部分差异表达基因与在绝经后骨质疏松症患者和正常绝经女性血液中差异表达的基因取交集,获得两对比组中共同差异表达的基因。通过基因本体论数据库(GO)对获得的共同差异表达基因分别从生物过程(BP)、分子功能(MF)和细胞组分(CC)三方面进行功能富集分析;利用京都基因和基因组百科全书数据库(KEGG)进行通路富集分析。利用生物通用交互数据集库(BioGRID)分析获得与共同差异表达基因产物互作的蛋白质,并构建蛋白质-蛋白质互作关系(PPI)网络,采用Cytoscape软件实现蛋白质-蛋白质互作关系网络的可视化。应用中医药数据库(BATMAN-TCM)对六味地黄丸主要中药成分的靶标基因进行预测。结果六味地黄丸干预后,得到1 350个差异表达基因,其中上调表达基因322个,下调表达基因1 027个。58个共同差异表达基因与六味地黄丸干预绝经后骨质疏松的分子机制相关,六味地黄丸干预后43个基因下调,15个基因上调。六味地黄丸主要中药成分的10个共同差异表达基因靶标为ESR1, FGFR2, MED1, PGR, PRKCB, PTGS1, PTGS2, TRIM24, VDR, WNT4。与六味地黄丸干预组差异表达基因对比分析,ATF2, FBXW7以及RDX基因在干预后呈现显著差异表达。结论 ATF2, FBXW7和RDX基因为参与六味地黄丸干预绝经后骨质疏松分子调控机制的关键基因。六味地黄丸主要中药成分的10个共同靶标基因中,ESR1, FGFR2, MED1, WNT4为六味地黄丸干预治疗绝经后骨质疏松等相关内分泌疾病的潜在调控基因。     

六味地黄丸临床研究进展

本文通过对六味地黄丸临床研究进展的回顾性分析,对六味地黄丸的临床应用做一系统总结.六味地黄丸自宋代创制以来,其临床主治病证不断扩大,广泛应用于心脑血管、内分泌、泌尿生殖等临床各科疾病.这种多系统、多病种的广泛性的治疗作用为我们提出了全新的课题.因此,深入研究六味地黄丸的主治病证以及其作用机理,结合现代疾病深入探讨肾阴虚证或肝肾阴虚证的病理实质,对进一步揭示中医异病同治的理论基础和提高临床治疗水平将具有重要的意义.     

六味地黄丸对绝经期后反复尿路感染防治作用的临床研究

目的探讨六味地黄丸对绝经期后反复尿路感染的防治作用.方法采用随机对照方法,将符合标准的68例分为治疗组和对照组,治疗组36例,口服六味地黄丸（浓缩丸）,对照组32例,口服谷维素,观察2个月.两组均予对症处理.结果治疗组尿路感染次数显著减少（P＜0.05）,对照组变化不大（P＞0.05）,且治疗纽尿感次数显著低于对照组（P＜0.01）;治疗中每次尿感时近期治愈时间,治疗组显著短于对照组（P＜0.01）;治疗组中医证候积分值较治疗前下降显著（P＜0.01）,且其下降幅度亦显著优于对照组（P＜0.01）;尿SIgA及血雌二醇水平,治疗组均提高显著（P＜0.01）,而对照组变化不明显（P＞0.05）.结论六味地黄丸对绝经期后反复尿路感染有显著的预防与治疗作用,值得临床推广应用.     

运用UV-Vis考察五子衍宗丸物质组释放特征

目的:考察不同释放度测定装置、不同转数和不同释放介质对五子衍宗丸丸物质组释放特性的影响及不同批号、不同厂家五子衍宗丸物质组释放特性。方法:运用中药物质(化合物)组释放动力学方法,以紫外吸收光谱法测定并计算各供试品溶液的物质组浓度及释放度。结果:溶出度测定条件为:采用浆法,转速100 r/min,以脱气蒸馏水为释放介质。测定结果显示:不同厂家或同一厂家不同批号物质组释放动力学特征存在显著性差异(P<0.01)。结论:中药物质组释放动力学评价方法符合中医药的整体观,揭示了多组分中药及其复方制剂的释放动力学特征。     

名中医治疗狼疮性肾炎的文献理论研究

目的了解名老中医对狼疮性肾炎的治疗现状,吸取经验,提高临床治疗效果。方法检索了2002～2012年公开发表的名中医治疗狼疮性肾炎的经验、体会等文献,最终纳入分析的文献29篇,涉及26位中医及中西医结合专家,对文中涉及的邪实因素、中医辨证治疗中各证型及用方在文献中出现的次数进行统计分析。结果①专家认为狼疮性肾炎病变过程中涉及邪实因素以热毒、瘀血、湿热出现频率最高,三者分别占34.92%、30.16%及14.29%。②辨证分型中以热毒炽盛、气阴两虚、肝肾阴虚、脾肾阳虚、阴虚内热占有主导地位。③方剂使用频率排在前八位的分别为知柏地黄汤、犀角地黄汤、六味地黄丸、二至丸、清瘟败毒饮、真武汤、金匮肾气丸、参芪地黄汤。     

不同厂家六味地黄丸溶散与释药特性的比较

目的:评价六味地黄丸物质组释放动力学特性、溶散特征及其相关性。方法:选择甲乙丙3个厂家的六味地黄丸,其中甲厂家采集了3个批号的样本,采用中药物质组释放度评价技术与方法,参照2010年版《中国药典》,以桨法测定各时间点释放度,拟合释放曲线,计算释放动力学特征参数;检测各厂家批号六味地黄丸的溶散时间;分析六味地黄丸释药特征参数与其溶散时间的相关性。结果:六味地黄丸具有一定的缓释特征,动力学特征符合Weibull释放模型,计算各Weibull分布参数T50和Td。甲、乙、丙三厂家丸剂的T50分别为107.01,134.33,13.01 min,Td分别为234.11,292.33,37.66 min,均有显著性差异(P0.01);厂家甲3个批号丸剂的T50分别为107.01,125.93,194.44 min,Td分别为234.11,385.42,206.17 min,批次间也有显著差异(P0.01);厂家甲(3个批号)、乙、丙六味地黄丸的溶散时间依次为32,43,37,35,21 min,符合《中国药典》要求,但存在一定差异;六味地黄丸的释药速率参数T50,Td与其溶散时间之间均具有显著的正线性相关关系(P0.05)。结论:六味地黄丸的物质组释放动力学特征存在显著的厂间、批间差异,其释药速率与溶散时间具有相关性。     

六味地黄丸临床研究进展

本文通过对六味地黄丸临床研究进展的回顾性分析,对六味地黄丸的临床应用做一系统总结。六味地黄丸自宋代创制以来,其临床主治病证不断扩大,广泛应用于心脑血管、内分泌、泌尿生殖等临床各科疾病。这种多系统、多病种的广泛性的治疗作用为我们提出了全新的课题。因此, 深入研究六味地黄丸的主治病证以及其作用机理,结合现代疾病深入探讨肾阴虚证或肝肾阴虚证的病理实质,对进一步揭示中医异病同治的理论基础和提高临床治疗水平将具有重要的意义。     

六味地黄丸延缓衰老的临床研究及其药理实验研究

目的 探讨六味地黄丸延缓衰老的临床疗效及其作用机理。方法将符合标准的292例患者分为治疗组和对照组，治疗组242例，口服六味地黄丸，对照组50例，口服安慰剂。并进行相应的动物实验观察六味地黄丸延缓衰老的作用。结果治疗组肾虚衰老治疗后症状积分值，比治疗前有显著性差异（P〈0．001，P〈0．01）；安慰剂对照组治疗前后无明显区别。近视力、握力、心理衰老、瞬时记忆积分等，应用六味地黄丸后均有显著改善（P〈0．01）；安慰剂对照组无明显差异。血清过氧化脂质、肾上腺皮激素，超氧化物歧化酶、血浆睾酮、雌二醇、细胞免疫功能等方面，治疗组比治疗前有显著改善（P〈0．01）；对照组变化不明显。药理学研究证明，六味地黄丸具有滋补肝肾、降血压、抗心律失常、降血脂、抗动脉硬化、降血糖、抗应激等作用。结论六味地黄丸具有延缓衰老的功效，且具有一定的药理学基础。